Clinical Report: Intracranial Hemorrhage Recurrence Following VEGFR TKI Rechallenge

Overview

This report presents a case of recurrent intracranial hemorrhage in a patient with metastatic renal cell carcinoma following the rechallenge of VEGFR TKI therapy. The findings indicate that early re-administration of VEGFR TKIs after CNS hemorrhage may pose significant risks.

Background

Intracranial hemorrhage is a rare but serious adverse effect associated with VEGFR TKIs, which are standard treatments for metastatic renal cell carcinoma (RCC). Understanding the safety of VEGFR TKI rechallenge after CNS hemorrhage is crucial, as treatment options for relapsed metastatic RCC are limited. This case emphasizes the need for careful risk assessment before re-administration of these agents.

Data Highlights

No numerical data or trial data available in the article.

Key Findings

• A 52-year-old man with metastatic clear cell RCC developed multifocal cerebellar hemorrhages after VEGFR TKI therapy.
• Initial treatment with ipilimumab and nivolumab was followed by sunitinib, which achieved a partial response.
• Rechallenge with pazopanib after surgical management of hemorrhage led to recurrent cerebellar hemorrhage within 4 weeks.
• The patient experienced rapid clinical deterioration and death despite supportive care.
• Early VEGFR TKI rechallenge (<1–2 months) after CNS hemorrhage may be unsafe.

Clinical Implications

Healthcare professionals should exercise caution when considering the re-administration of VEGFR TKIs in patients with a history of CNS hemorrhage. A thorough risk-benefit assessment and an adequate waiting period are essential before rechallenging with these agents.

Conclusion

This case highlights the potential risks of recurrent intracranial hemorrhage associated with VEGFR TKI rechallenge in patients without brain metastases. Further studies are needed to establish safe protocols for managing such patients.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. Effectiveness of Immune Checkpoint Inhibitors in Reducing Venous Tumor Thrombus in Renal Cell Carcinoma (UroCCR 128)
3. VEGFR Tyrosine Kinase Inhibitors Linked to Increased Risk of Fatal Adverse Events
4. ESMO Living Guideline: Renal Cell Carcinoma | ESMO
5. Frontiers in Oncology — Case Report: Dynamic TKI combination strategies for EGFR-mutant NSCLC with acquired ROS1 fusion and brain metastases
6. Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial
7. ESMO Living Guideline: Renal Cell Carcinoma | ESMO
8. These highlights do not include all the information needed to use CABOMETYX safely and effectively. See full prescribing information for CABOMETYX. CABOMETYX® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012